CIK 0001622229
- Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 465308248
- Phone
- +1 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-04-03 | FMR LLC | Conversion · Series A Preferred Stock | −35,614 | 0 | ||
| 2018-04-03 | FMR LLC | Conversion · Series B Preferred Stock | −13,505 | 0 | ||
| 2018-04-03 | FMR LLC | Conversion · Series B Preferred Stock | −73,065 | 0 | ||
| 2018-04-03 | FMR LLC | Conversion · Series B Preferred Stock | −877 | 0 | ||
| 2018-04-03 | Ratcliffe Liam Director | Conversion | +622,772 | 622,772 | ||
| 2018-04-03 | Ratcliffe Liam Director | Conversion | +622,773 | 622,773 | ||
| 2018-04-03 | Ratcliffe Liam Director | Purchase | +275,000 | $12.00 | $3.3M | 897,772 |
| 2018-04-03 | Ratcliffe Liam Director | Purchase | +275,000 | $12.00 | $3.3M | 897,773 |
| 2018-04-03 | Ratcliffe Liam Director | Conversion · Series B Preferred Stock | −977,835 | 0 | ||
| 2018-04-03 | Ratcliffe Liam Director | Conversion · Series B Preferred Stock | −977,836 | 0 | ||
| 2018-04-03 | Atlas Venture Fund IX, L.P. 10% owner | Conversion | +3,184,446 | 3,184,446 | ||
| 2018-04-03 | Atlas Venture Fund IX, L.P. 10% owner | Conversion | +83,037 | 3,267,483 | ||
| 2018-04-03 | Atlas Venture Fund IX, L.P. 10% owner | Purchase | +94,052 | $12.00 | $1.1M | 3,361,535 |
| 2018-04-03 | Atlas Venture Fund IX, L.P. 10% owner | Conversion · Series A Preferred Stock | −3,184,446 | 0 | ||
| 2018-04-03 | Atlas Venture Fund IX, L.P. 10% owner | Conversion · Series B Preferred Stock | −83,037 | 0 | ||
| 2018-04-03 | Booth Bruce Director | Conversion | +3,184,446 | 3,184,446 | ||
| 2018-04-03 | Booth Bruce Director | Conversion | +83,037 | 3,267,483 | ||
| 2018-04-03 | Booth Bruce Director | Purchase | +94,052 | $12.00 | $1.1M | 3,361,535 |
| 2018-04-03 | Booth Bruce Director | Conversion · Series A Preferred Stock | −3,184,446 | 0 | ||
| 2018-04-03 | Booth Bruce Director | Conversion · Series B Preferred Stock | −83,037 | 0 |
Page 16 of 16 · 320 trades